RMD Open

Assessment of the minimal clinically important difference for the Health Assessment Questionnaire Disability Index in patients with arthralgia at risk for progression to ...

Introduction Patients with arthralgia at-risk for rheumatoid arthritis (RA) experience considerable functional disability, though generally less than at RA diagnosis. Secondary prevention trials have ...
rmdopen.bmj

Low prevalence of anti-SSA (anti-Ro) and anti-SSB (anti-La) autoantibodies in female patients with rheumatoid arthritis with a wish to conceive

Objectives Guidelines advise to test for anti–Sjögren's-syndrome-related antigen A (anti-SSA) and anti–Sjögren's-syndrome-related antigen B (anti-SSB) antibodies in all patients with rheumatoid ...
RMD Open

Active vitamin D acts in vitro as an adjuvant to anti-TNFα treatment in a psoriatic synovial fibroblast activation model by modulating human Th17 activity

TNF-driven inflammatory arthritis, commonly accompanied by vitamin D deficiency. Here, we investigate the interaction between ...
RMD Open

Are investigator-initiated clinical trials becoming an ‘endangered species’?

Investigator-initiated clinical trials (IITs) are at the core of innovative thinking in health research generating data in ...
rmdopen.bmj

Early effects of ozoralizumab 30 mg in patients with rheumatoid arthritis and inadequate response to methotrexate: a post hoc trajectory analysis of the phase II/III OHZORA trial

Objective This study assessed the early effects of ozoralizumab (OZR) 30 mg in patients with rheumatoid arthritis (RA) with inadequate response to methotrexate (MTX-IR), drawing on OHZORA trial data ...
rmdopen.bmj

ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI)

Objective(s) This study evaluated the interaction of anticitrullinated protein antibody (ACPA) and rheumatoid factor (RF) in predicting sustained clinical response in an observational registry of ...
rmdopen.bmj

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study

Background In SELECT-PsA 1, a randomised double-blind phase 3 study, upadacitinib 15 mg and 30 mg were superior to placebo and non-inferior to adalimumab in ≥20% improvement in American College of ...
rmdopen.bmj

Vascular ultrasound for the diagnosis of giant cell arteritis: a reliability and agreement study based on a standardised training programme

Objective To evaluate the impact of a standardised training programme including equipment adjustment for experienced musculoskeletal ultrasonographers without previous experience in vascular ...
rmdopen.bmj

Factors influencing bone loss in anorexia nervosa: assessment and therapeutic options

Decreased mineral density is one of the major complications of anorexia nervosa. The phenomenon is even more pronounced when the disease occurs during adolescence and when the duration of amenorrhoea ...
rmdopen.bmj

Hydroxychloroquine and pregnancy outcomes in patients with anti-phospholipid syndrome: a systematic review and meta-analysis

Background About 20% of female patients with anti-phospholipid syndrome (APS) experience obstetric complications despite standard treatment with aspirin and heparin. Treatment with hydroxychloroquine ...
rmdopen.bmj

Using ultrasound to define inflammatory and non-inflammatory phenotypes in difficult-to-treat psoriatic arthritis

Objective To investigate the prevalence of difficult-to-treat psoriatic arthritis (D2T-PsA) and classify patients with persistent inflammatory PsA (PIPsA) and non-inflammatory PsA (NIPsA) based on a ...
rmdopen.bmj

Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies

Objective To assess the efficacy of long-term treatment with risankizumab across the updated Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains and key related ...